Article

Proposing Response Evaluation Criteria in Solid Tumors Based on Genomic Profiling or Genomic RECIST: A Retrospective Study on the Liquid Biopsy Results of 29 Cancer Patients

2021-12-14

Abstract excerpt

Tumor response and disease progression are assessed using imaging technologies. However, these technologies fail to detect tumor responses at the molecular level and clonal evolution. A potential surrogate for such parameters is using circulating tumor DNA (ctDNA). This study aimed to examine the quantity and composition of the ctDNA results of 29 cancer patients before and after dendritic cell (DC) immunotherapy...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6be717f0-9ea3-5d53-9846-961c10c1555f
DOI: 10.1101/2021.12.13.21266491

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Proposing Response Evaluation Criteria in Solid Tumors Based on Genomic Profiling or Genomic RECIST: A Retrospective Study on the Liquid Biopsy Results of 29 Cancer PatientsDOI 10.1101/2021.12.13.21266491Read

Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors.Semantic proximity Read

Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors.Semantic proximity Read

Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab.Semantic proximity Read

Clinical implications of circulating tumor DNA in predicting the outcome of first line treatment in diffuse large B-cell lymphoma (DLBCL) patientsSemantic proximity Read

Blood, toil, and taxoteres: Biological determinants of treatment-induced ctDNA dynamics for interpreting tumor response.Semantic proximity Read

Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting.Semantic proximity Read

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer PatientsSemantic proximity Read

Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients.Semantic proximity Read

Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)Semantic proximity Read

Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging.Semantic proximity Read

Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers.Semantic proximity Read

Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy.Semantic proximity Read